Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Main Inclusion Criteria * Documented informed consent of the participant and/or legally authorized representative. * Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval. * Age 18 years and older. * KPS ≥ 70%, ECOG ≤ 2 (Appendix A). * Life expectancy ≥ 4 weeks. * Participant has a prior histologically confirmed diagnosis of a glioblastoma (IDH-wildtype) or grade 4 IDH-mutant astrocytoma, or has a prior histologically confirmed diagnosis of a grade 2 or 3 astrocytoma and now has radiographic progression consistent with grade 4 IDH-mutant astrocytoma. * Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy (such as temozolomide with or without Optune device), and ≥ 12 weeks after completion of front-line radiation therapy. * COH Clinical Pathology assessment at the initial tumor presentation or recurrent disease (reference Appendix B): * IL13Rα2+ expression by IHC \> 20, and * EGFR gene-altered by NGS or FISH analysis * No known contraindications to leukapheresis, steroids, imaging studies, or tocilizumab. * WBC \> 2000 /dl (or ANC ≥ 1,000/mm3) * Platelets ≥ 75,000/mm3 * Hemoglobin \> 9g/dL * Total bilirubin ≤ 1.5x ULN * AST ≤ 2.5x ULN * ALT ≤ 2.5x ULN * Serum creatinine ≤1.6 mg/dL * O2 saturation ≥ 95% on room air. * Seronegative for HIV Ag/Ab combo, HCV, and active HBV * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells. Main Exclusion Criteria * Owing to higher frequency of wound-related complications, participants who require active bevacizumab therapy at the time of enrollment are excluded. * Participant has not yet recovered from toxicities of prior therapy. * Participant has received any live vaccine within 30 days prior to enrollment. * Uncontrolled seizure activity and/or clinically evident progressive encephalopathy. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent. * Clinically significant uncontrolled illness. * Active autoimmune disease requiring systemic immunosuppressive therapy * Active infection requiring IV antibiotics (for example, minor scalp infection is not exclusion). * Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection. * Other active malignancy. * Females only: Pregnant or breastfeeding. * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures. * Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).